StockData
Kailera Therapeutics, Inc. logo

Kailera Therapeutics, Inc. (KLRA) stock

KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$12.20−0.37 (-2.94%)

Close on Nov 17, 2026Market cap $1.58BP/E –Yield –

Kailera Therapeutics EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Quarterly eps

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$0.74–
Q2 FY2026Jun 30, 2026-$1.09–
Q1 FY2026Mar 31, 2026-$3650.00–
Q3 FY2025Sep 30, 2025-$39623.00–
Q2 FY2025Jun 30, 2025-$28947.00–
Q1 FY2025Mar 31, 2025-$17983.00–

More Kailera Therapeutics figures

See a number that looks wrong?